Erik Harris, Elan
S
Erik Harris
Senior Director, Sales and Marketing, Tysabri, Elan
IS BUSY WITH: Newborn twins
BIGGEST ACCOMPLISHMENT: The blockbuster growth of Rituxan
I'm a person that loves challenges," says Erik Harris. And it must be true—otherwise, he wouldn't be heading up the sales and marketing effort for Tysabri and it's new Crohn's Disease indication. "The safety issues, and the fact that patients and doctors have to enroll in a RiskMAP to be on it, make it a difficult product to sell," concedes Harris. "But it's worth it because, for some patients, there are no other options."
Erik Harris
Perhaps even more valuable than his previous work experience building the brands of Rituxan and Tarceva at Genentech, are the lessons Harris learned while serving as a naval aviator for the military. "If you can implement ideas and get people to move forward and change things in that bureaucratic system, well then, those skills translate."
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
